Who
Sandeep Chidambar Kulkarni
Director and Chairman
Company insider
Files Form 4 as: Director and Chairman, Amanat Acquisition; Chief Executive Officer, Zura Bio; CEO, Tourmaline Bio.
In numbers
- Trades disclosed
- 28
- Buys
- 6
- Sells
- 0
- Bought
- $277K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 18 May 2023
- Last trade
- 2 Jul 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jul 2026filed 12 Aug 2026 | AMAN Amanat Acquisitionoption or derivative · Funds, Shells & SPACs | SEC FORM 4 Code J | —281,250 at $0.00 | filing |
| 2 Jul 2026filed 12 Aug 2026 | AMAN Amanat Acquisitionoption or derivative · Funds, Shells & SPACs | SEC FORM 4 Code J | —281,250 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | AMAN Amanat AcquisitionFunds, Shells & SPACs | SEC FORM 4 Bought | —300,000 | filing |
| 20 May 2026filed 22 May 2026 | AMAN Amanat AcquisitionFunds, Shells & SPACs | SEC FORM 4 Bought | —300,000 | filing |
| 1 Apr 2026filed 2 Apr 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —894,000 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —894,000 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —2,934,107 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —2,934,107 at $0.00 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —503,478 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —254,207 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —226,000 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Bio | SEC FORM 4 Code U | —724,664 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Bio | SEC FORM 4 Code D | —30,387 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Bio | SEC FORM 4 Code U | —7,000 | filing |
| 22 Oct 2025filed 24 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code M | —25,316 at $0.00 | filing |
| 22 Oct 2025filed 24 Oct 2025 | Tourmaline Bio | SEC FORM 4 Code M | $200K25,316 at $7.90 | filing |
| 21 May 2025filed 22 May 2025 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code A | —226,000 at $0.00 | filing |
| 9 Dec 2024filed 11 Dec 2024 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —117,000 at $0.00 | filing |
| 21 Aug 2024filed 22 Aug 2024 | Tourmaline Bio | SEC FORM 4 Bought | $26K1,779 at $14.85 | filing |
News
No headline names them, or the companies they trade most, lately.